Arbutus Biopharma is a publicly-traded (NASDAQ:ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease. Source
No articles found.
CASI is a U.S. NASDAQ-listed biopharmaceutical company focused on developing and a...
CASI is a U.S. NASDAQ-listed biopharmaceutical ...
At Sesen Bio, we are committed to renewing life for people with cancer. We are a l...
At Sesen Bio, we are committed to renewing life...
Change Healthcare is a leading independent healthcare technology company that prov...
Change Healthcare is a leading independent heal...
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...
IMV Inc. is a clinical stage biopharmaceutical ...
Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...
Neoleukin is a biopharmaceutical company creati...
ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, de...
ChemoCentryx is a biopharmaceutical company foc...
Assembly Biosciences is advancing a new class of oral therapeutics for the treatme...
Assembly Biosciences is advancing a new class o...
Join the National Investor Network and get the latest information with your interests in mind.